| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Comments From Dendreon's Conference Call (may 10, 2007)
Posted on 05/12/2007 14:26:25 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
Dendreon (DNDN) hosted a painful conference call today, and despite management answering most questions you could hear some frustration and disappointment out of management. The FDA has requested additional data but not specified what form of data. The impact study is double blind and placebo controlled Phase III study under a binding FDA agreement. This will serve as the basis and they will complete and interim analysis next year and a final analysis in 2010.
The company is maintaining that they are committed to this process. As far as earnings for the quarter, but earnings are irrelevant because revenues were a whopping $80,000.00. It had $88+ million cash and equivalents at the end of the quarter and they think the cash is adequate to get them through to interim analysis in 2008.
Please continue reading further because the list goes on and some people jumped back in the line to ask questions. These are brief summary comments rom the Q&A session and some of the answers and questions were only able to be partially caught:
Continue article at 247WallSt.com
RELATED READING:
- Dendreon Gets Complete Response Letter
- Dendreon Nailed by FDA
- Dendreon Option Premiums Remain Astronomical
____________________
24/7 Wall St.
Dendreon (DNDN) hosted a painful conference call today, and despite management answering most questions you could hear some frustration and disappointment out of management. The FDA has requested additional data but not specified what form of data. The impact study is double blind and placebo controlled Phase III study under a binding FDA agreement. This will serve as the basis and they will complete and interim analysis next year and a final analysis in 2010.The company is maintaining that they are committed to this process. As far as earnings for the quarter, but earnings are irrelevant because revenues were a whopping $80,000.00. It had $88+ million cash and equivalents at the end of the quarter and they think the cash is adequate to get them through to interim analysis in 2008.
Please continue reading further because the list goes on and some people jumped back in the line to ask questions. These are brief summary comments rom the Q&A session and some of the answers and questions were only able to be partially caught:
Continue article at 247WallSt.com
RELATED READING:
- Dendreon Gets Complete Response Letter
- Dendreon Nailed by FDA
- Dendreon Option Premiums Remain Astronomical
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Trader X
- Real Estate Marketing Blog
- Morpheus Trading
- Alpha Trends
- Millionaire Now! by Larry Nusbaum
- Random Roger's Big Picture
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home